Teleflex Continues Restructuring By Selling Hudson Respiratory Business To Medline
Executive Summary
Medline will pay $286m in cash for Teleflex's oxygen and aerosol therapy, active humidification, and non-invasive ventilation devices as well as incentive spirometers. Those businesses yielded $139m in 2020 revenues, but do not fit into Teleflex's plan for the future.
You may also be interested in...
Teleflex Adds Hemostatic Products With $525M Acquisition Of Z-Medica
Z-Medica’s wound care products, led by its QuikClot Control+ hemostatic dressing, complement Teleflex’s existing line of products marketed to first responders and the military.
Cardiovascular Catch-Up: Spring Brings Bloom Of New Clinical Trial Results And Launches
April and May were full of cardiovascular professional society conferences, yielding important new research results along with announcements of major new clinical trials. Here are a few of the highlights.
Device Week, 9 June 2021 – ATTD Medtronic Update; CVRx IPO
In this week’s podcast, Medtech Insight's UK-based reporter Barnaby Pickering provides an update on Medtronic’s MiniMed 780G insulin pump cost-savings study, presented at the Advances Technologies & Treatments for Diabetes (ATTD) conference. US Commercial and R&D manager, Reed Miller, highlights details on CVRx’s recent IPO.